Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Recursion · Project update · October 15, 2026
Recursion shared positive Phase 2 results for REC-4881, an investigational treatment for familial adenomatous polyposis. The data showed significant reductions in polyp burden across the gastrointestinal tract, particularly in high-risk upper GI areas.
AntSpace’s summary of Recursion’s own announcement: read the original.